Routine Tandem Transplantation for Patients with Myeloma
Authors: Kevin Imrie
Journal: Annals of Internal Medicine (2003)

Letters1 July 2003Routine Tandem Transplantation for Patients with MyelomaKevin Imrie, MD and Ralph M. Meyer, MDKevin Imrie, MDTorontoSunnybrook Regional Cancer Center; Toronto, Ontario M4N 3M5, Canada (Imrie)Hamilton Regional Cancer Centre; Hamilton, Ontario L8V 5C2, Canada (Meyer) Note added in proof: The data described are based on work completed in August 2002. The Hematology Site Group of the Cancer Care Ontario Practice Guidelines Initiative is aware of a published abstract (5) that includes an updated analysis of the trial reported by Attal and Harousseau (2). The Hematology Site Group will incorporate these new data into an updated practice guideline. These new data have not resulted in changes to previous recommendations that are posted on our Web site (1).Search for more papers by this author and Ralph M. Meyer, MDTorontoSunnybrook Regional Cancer Center; Toronto, Ontario M4N 3M5, Canada (Imrie)Hamilton Regional Cancer Centre; Hamilton, Ontario L8V 5C2, Canada (Meyer) Note added in proof: The data described are based on work completed in August 2002. The Hematology Site Group of the Cancer Care Ontario Practice Guidelines Initiative is aware of a published abstract (5) that includes an updated analysis of the trial reported by Attal and Harousseau (2). The Hematology Site Group will incorporate these new data into an updated practice guideline. These new data have not resulted in changes to previous recommendations that are posted on our Web site (1).Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-1-200307010-00020-w2 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that to assess the role of tandem transplantation in patients with multiple myeloma, potential benefits and risks need to be balanced and utilization of health care resources considered. In developing formal guidelines, it is essential that available evidence be systematically appraised. For our guideline, we completed a systematic literature review by using predefined criteria to select available literature. Greatest weight was given to articles or abstracts reporting results of randomized trials; case series were not considered. We regularly update this literature search and, if appropriate, consider guideline revisions to incorporate new evidence. An update of our ...References1. Imrie K, Makarski J, Esmail R, Meyer RM. Optimal therapy for patients diagnosed with multiple myeloma and the role of high-dose chemotherapy and stem cell support. Cancer Care Ontario Practice Guideline Initiative. Available at www.ccopebc.ca/guidelines/hem/cpg6_6.html. Google Scholar2. Attal M, Harousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol. 2001;38:226-30. [PMID: 11486310] CrossrefMedlineGoogle Scholar3. Cavo M, Tosi P, Zamagni E, Ranconi S, Cellini C, Cangini D, et al. The Bologna 96 trial of single vs. double PBSC transplantation for previously untreated MM: results of an interim analysis. In: Abstract Book of the VIIIth International Myeloma Workshop, Banff, Alberta, Canada, 48 May 2001. 29-30 (S16). Google Scholar4. Fermand JP, Marolleau JP, Alberti C, Divine M, Leblond V, Macro M, . In single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [Abstract]. Blood. 2001;99:815a. Google Scholar5. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, . Double autologous transplantation improves survival in multiple myeloma patients: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome [Abstract]. Blood. 2002;100:5a. Google Scholar Author, Article, and Disclosure InformationAffiliations: TorontoSunnybrook Regional Cancer Center; Toronto, Ontario M4N 3M5, Canada (Imrie)Hamilton Regional Cancer Centre; Hamilton, Ontario L8V 5C2, Canada (Meyer) Note added in proof: The data described are based on work completed in August 2002. The Hematology Site Group of the Cancer Care Ontario Practice Guidelines Initiative is aware of a published abstract (5) that includes an updated analysis of the trial reported by Attal and Harousseau (2). The Hematology Site Group will incorporate these new data into an updated practice guideline. These new data have not resulted in changes to previous recommendations that are posted on our Web site (1). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 2003Volume 139, Issue 1Page: W-55KeywordsCase seriesFactorial designHealth care utilizationIntent to treat analysisMultiple myelomaMyelomaRandomized trialsStem cellsSystematic reviewsTransplantation ePublished: 1 July 2003 Issue Published: 1 July 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...